BOSTON THERAPEUTIC (BTHE)

0.09
0.01 18.58
OTC
Prev Close 0.08
Open 0.08
Day Low/High 0.08 / 0.09
52 Wk Low/High 0.03 / 0.12
Volume 183.43K
Exchange OTC
Shares Outstanding 108.01B
Market Cap 8.10M
Div & Yield N.A. (N.A)

Latest News

Boston Therapeutics Creates New Scientific Advisory Board

Boston Therapeutics Creates New Scientific Advisory Board

Strategic Medical Advisory with Relevant Pharmaceutical Guidance is Added to Expand the Strategic Development

Boston Therapeutics Announces New COO, Loraine V. Upham

Boston Therapeutics Announces New COO, Loraine V. Upham

Former Founder of CureDM to Run US Operations

Boston Therapeutics Announces Strategic Acquisition Of CureDM

Boston Therapeutics Announces Strategic Acquisition Of CureDM

New Peptide Therapeutic adds to Pipeline of Novel Approaches to Diabetes

Boston Therapeutics, Inc. Expands Partnership With APC To Distribute In Korea

Boston Therapeutics, Inc. Expands Partnership With APC To Distribute In Korea

New Introduction Strategies in Asia/US to Generate Awareness of CGM importance

Boston Therapeutics, Inc. Announces New Dosing Regimen For BTI320

Boston Therapeutics, Inc. Announces New Dosing Regimen For BTI320

Now Recommended for Single Tablet Consumption

Boston Therapeutics Shareholder Update

Boston Therapeutics Shareholder Update

BOSTON THERAPEUTICS Reports Data From The POC Asia Trial At The American Diabetes Association's 77th Scientific Sessions

A Study to Evaluate the Effect of BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycemia in High Risk Chinese Subjects with Pre-Diabetes

SeeThruEquity Issues Quarterly Update On Boston Therapeutics

SeeThruEquity Issues Quarterly Update On Boston Therapeutics

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Boston...

[video] New Tablet From Boston Therapeutics Reduces Sugar Intake for Diabetics

[video] New Tablet From Boston Therapeutics Reduces Sugar Intake for Diabetics

Boston Therapeutics new PAZ320 tablet is designed to reduce a person's sugar intake before eating a meal.

Boston Therapeutics' New Tablet Reduces Sugar Intake for Diabetics

Boston Therapeutics' New Tablet Reduces Sugar Intake for Diabetics

Boston Therapeutics new PAZ320 tablet is designed to reduce a person's sugar intake before eating a meal.